Hexarelin vs Ipamorelin
Which Is Right for You? Complete Comparison (2026)
Hexarelin vs Ipamorelin comparison — most potent GHRP vs cleanest side-effect profile, cardiac CD36 protection angle, cortisol/prolactin differences.
Hexarelin vs Ipamorelin: At a Glance
- ✓Most potent GH-releasing hexapeptide in the GHRP family
- ✓Stimulates GH via ghrelin receptor with strong acute pulse
- ✓Direct cardioprotective effects independent of GH release
- ✓Significant cortisol and prolactin elevation
- ✓Subject to desensitization with chronic use (GH response fades)
- ✓Selective growth hormone releasing peptide (GHRP)
- ✓Stimulates pituitary GH release via ghrelin/GHS-R1a receptor
- ✓Does not significantly elevate cortisol, prolactin, or aldosterone
- ✓Produces a clean GH pulse similar to natural secretion
- ✓Half-life approximately 2 hours — administered 2-3x daily
Detailed Comparison
| Feature | Hexarelin | Ipamorelin |
|---|---|---|
| Mechanism | Growth hormone releasing hexapeptide | Growth hormone secretagogue (selective GHRP)Best |
| Dosing | 100-200 mcg SC 2-3x daily (cycling recommended) | 200-300 mcg SC 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~70 minutes | ~2 hours |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — research peptide |
| Key Trial | Arvat E et al. JCEM 2001 — GH secretagogue comparison | Raun K et al. Eur J Endocrinol 1998 — demonstrated selective GH release |
| Side Effects | Cortisol/prolactin elevation, desensitization, water retention | Headache, flushing, dizziness, injection site irritation — generally well-tolerated |
Which Should You Choose?
Hexarelin (growth hormone releasing hexapeptide) and Ipamorelin (growth hormone secretagogue (selective ghrp)) serve different clinical roles despite both being in the GH secretagogue space. Hexarelin potent synthetic gh secretagogue with strongest gh release of the ghrp family. Ipamorelin selective gh secretagogue that stimulates gh release from the pituitary via ghrelin receptor without significantly raising cortisol, prolactin, or aldosterone.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Hexarelin and Ipamorelin
Choosing between Hexarelin and Ipamorelin depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Hexarelin and Ipamorelin is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Hexarelin vs Ipamorelin: Frequently Asked Questions
Yes — hexarelin is the most potent GHRP per mcg, producing the highest peak GH release of any GHRP at equivalent doses. However, hexarelin also causes cortisol, prolactin, and ACTH elevation alongside GH release, and causes pituitary desensitization within 4–6 weeks. Ipamorelin is highly selective for GH release only, with minimal cortisol or prolactin elevation and less desensitization — making it more suitable for sustained use.
Yes — hexarelin has a unique cardiac protection mechanism via CD36 receptor binding on cardiomyocytes, activating cardioprotective signaling independent of GH/IGF-1. Animal studies show hexarelin protects against ischemia-reperfusion injury and reduces cardiomyocyte apoptosis — effects not seen with ipamorelin.
For most users, ipamorelin + CJC-1295 is the recommended starting point — it produces synergistic GH/IGF-1 elevation with minimal side effects and can be used continuously for 12+ weeks. Hexarelin + CJC-1295 produces higher peak GH but requires 4–6 week cycles due to desensitization. Hexarelin is preferred when cardiac protection or maximum GH pulse amplitude is the specific goal.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Hexarelin or Ipamorelin in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.